[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100275317":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":21,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"German CLL Study Group","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Michael Hallek, MD","German CLL Study Group, Department I of Internal Medicine University Hospital Cologne","STUDY_DIRECTOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Anna-Maria Fink, MD","CONTACT","+4922147888220","cllstudie@uk-koeln.de",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":18},"Central Study Office of the German CLL Study Group",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"BAG Freiberg-Richter, Jacobasch, Wolf, Illmer","RECRUITING","Dresden","Saxony","Germany","DE",{"type":30,"coordinates":31},"Point",[32,33],13.73832,51.05089,{"lat":33,"lon":32},[36],{"name":37,"role":16,"phone":7,"phoneExt":7,"email":7},"Lutz Jakobasch, MD",{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100275317","registry-of-the-german-cll-study-group-100275317",false,"NCT02863692","Registry of the German CLL Study Group","Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation","CLL-Registry","Inclusion Criteria (all must apply)\n\n1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation\n2. 18 years of age or older\n3. Signed, written informed consent\n4. Presence of one or more of the following disease situations:\n\n   * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial)\n   * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials)\n   * Referral for evaluation the indication for HSCT\n   * Relapsed disease status (even if first diagnosis was prior to activation of the registry)\n\nExclusion Criteria\n\n1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation\n2. Cerebral dysfunction, legal incapacity","ALL","18 Years",{"count":51,"type":52},8000,"ESTIMATED","25 Years","OBSERVATIONAL","Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T\u002FNatural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation",[57,58,59,60,61,62,63,64],"CLL","SLL","HCL","Richter´s Transformation","Leukemia, Prolymphocytic, B-Cell","Leukemia, Prolymphocytic, T-Cell","T-LGL Leukemia","NK-LGL Leukemia",[57,66,67,58,68,59,60],"B-PLL","T-PLL","T-NK-LGL","2025-12-01",{"date":71,"type":72},"2025-12-08","ACTUAL",{"date":74,"type":7},"2013-08",{"date":76,"type":52},"2026-12",{"name":5,"class":6},1]